Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept... ( Increases 2008 Adjusted EPS Guidance...)

Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008

Date:10/30/2008

Increases 2008 Adjusted EPS Guidance to $0.64 - $0.67 from Prior Range of

$0.47 - $0.53 Reaffirms Adjusted EPS Guidance of $0.90 - $1.10 for 2009 and $1.50 - $1.70

for 2010

PITTSBURGH, Oct. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced its financial results for the three and nine months ended Sept. 30, 2008.

Financial Highlights

-- Adjusted diluted EPS of $0.23 and $0.52 for the three and nine months ended Sept. 30, 2008, respectively, which excludes the impact of certain purchase accounting items as well as other non-recurring items as discussed in detail below;

-- Total revenues of $1.66 billion for the three months ended Sept. 30, 2008, an increase of $1.18 billion over the same prior year period;

-- Total revenues for the current quarter includes the recognition of approximately $455.0 million of previously deferred revenue related to the sale of the company's rights to Bystolic(TM);

-- On a GAAP basis the company reported earnings per diluted share of $0.45 for the three months ended Sept. 30, 2008, and a loss per diluted share of $0.92 for the nine months ended Sept. 30, 2008.

-- Included in the GAAP results for the year-to-date period is a non-cash goodwill impairment charge of $385.0 million recorded in the first quarter related to the Specialty Segment.

"As we have reached the one year anniversary of our acquisition of Merck KGaA's generics business, I am extremely pleased with the progress that we continue to make in combining the strengths of three high quality businesses, Mylan, Matrix and the former Merck Generics, into one well-positioned and powerful global platform. Led by a robust
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:

Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept...( Increases 2008 Adjusted EPS Guidance...)